This study aims to evaluate anxiety and cardiovascular outcomes in individuals with the psycho-cardio phenotype, characterized by clinically relevant anxiety symptoms with or without established cardiovascular disease (CVD). The study will be conducted as a prospective, real-world interventional study over 12 weeks. Participants will be allocated to either a group receiving Neurofast® supplementation (2 tablets per day) or a control group receiving no additional treatment. Psychological assessments will include the Generalized Anxiety Disorder Scale (GAD-7), Patient Health Questionnaire (PHQ-9), and Cardiac Anxiety Questionnaire (CAQ). Cardiovascular parameters, including heart rate, blood pressure, and electrocardiographic (ECG) measures, will also be evaluated. The primary objective is to assess changes in anxiety symptoms and heart rate over 12 weeks. Secondary objectives include evaluation of depressive symptoms, cardiovascular parameters, and treatment adherence in a real-world clinical setting.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change in Generalized Anxiety Disorder-7 (GAD-7) score
Timeframe: Baseline to Week 12
Change in Cardiac Anxiety Questionnaire (CAQ) score
Timeframe: Baseline to Week 12
Change in heart rate measured by standard 12-lead ECG
Timeframe: Baseline to Week 12
Change in PR interval measured by standard 12-lead ECG
Timeframe: Baseline to Week 12
Change in QRS duration measured by standard 12-lead ECG
Timeframe: Baseline to Week 12
Change in corrected QT interval (QTc) measured by standard 12-lead ECG
Timeframe: Baseline to Week 12